Biosimilars Market Research Report - Forecast till 2027

Biosimilars Market Research Report: By Product (Recombinant Non-Glycosylated Proteins (Human Growth Hormone [RHGH], Granulocyte Colony-Stimulating Factor [Filgrastim], Insulin and Interferons), Recombinant Glycosylated Proteins (Erythropoietin [EPO],  Monoclonal Antibodies [MABS] and Follitropin) and Recombinant Peptides [Glucagon and Calcitonin]), by Applications (Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases) - Forecast till 2027

ID: MRFR/LS/0821-HCR | February 2021 | Region: Global | 95 pages

Biosimilars Market Overview


Biosimilar is a term given to the medicines which are formulated and made similar to the approved biological medicines for treating some critical diseases. Biosimilar are approved medicines, manufactured to make critical but expensive medicines accessible and more affordable by the people who cannot afford the original form of a particular type of medicine. The biosimilars market is huge and working to facilitate the world with expensive medicine at a lower price.The biosimilars Market Size is expected to register a CAGR of 7.5% during the forecast period of 2019 to 2025, with a market value of USD 13,460 Million in 2018. An increase in chronic diseases and unaffordability to expensive medicines can be accounted as a major reason for the growth of the market and the rise in its Market value.  Apart from this, Europe was registered as the holder of the largest share of the market in2019 and Asia-Pacific is projected to register the highest growth of Biosimilars industry over the forecasted period. People adopted Biosimilar medicines as the substitute for original but expensive medicines and many people trust them. Moreover, key players of the market belong to the USA and hold the largest share of the market.

COVID-19 Analysis of Biosimilars Market 

These are difficult times and the whole world is facing problems and is afraid of viruses. People are focusing on increasing immunity and constantly clarifying if they are infection-free from the virus. Also, people are facing financial crises and many people who are already fighting some chronic diseases need those medicines more than any time. The outbreak of COVID-19 has triggered the growth of the Biosimilars Market as more biosimilar medicines are in demand than before.

About all types of Market has been severely or not, but affected by the pandemic that is caused due to COVID-19. Transportation of medicine has become difficult due to complete lockdown and only necessary and very important medicines are being imported or exported which is causing the blockages in the rate of growth of the market.

Regional Market Summary


Biosimilars Global Market Share by Region, 2018 (%)
 Biosimilars Market


Source: World Health Organization (WHO)


Biosimilars Market Dynamics


To understand the Biosimilars Market trends and opportunities, to understand different factors affecting Biosimilars industry Growth, market dynamics is required that covers drivers, restraints, opportunities, and challenges to the biosimilars market.


Drivers:


The factors that are contributing to the market growth and driving the growth of the Biosimilars market are:


Expiring Patent of Several Biological Drugs: Over the years, patents of many biological drugs have expired and patents of many will expire in a few years which is expected to increase the demand for Biosimilar Medicines.


Financial sustainability cost-Saving Initiatives: The main objective of Biosimilar medicines is to make critical medicines affordable to all. The government is taking initiatives in many countries to promote Biosimilar medicines.


Growing Geriatric Population: More Geriatric Population signifies more people prone to chronic diseases. Hence, higher demand for biosimilar medicines.


Opportunities:


Every market is always open to opportunities and is dependent on them for future expansion of the biosimilars market, its growth, and its scope.


Launch of new Biological Products: The biosimilars market can expand further and produce new forms of medicines when the original formulation and launch of the new biological product will come into the market.


Cost-Saving Sales: Biosimilar medicines can be accessible at the cost-saving amount to the Payer and the patient as well.


Restraints:


The factor controlling the Biosimilars Market growth is studied under restraints to the market:


Negative Perception: Many physicians and Doctors have a negative perception about biosimilar products and so they do not recommend their uses as well they demote their uses in the patient’s minds. This causes few people to restrict the use of biosimilar medicines.


Patent Extension: When the patent of original biological medicine does not expire or is expanded, then their biosimilar medicines cannot be produces


Challenges:


Challenges to the market can be converted into opportunities if tackled properly. Every Market has different challenges and tries different ways to overcome them. The challenges to Biosimilars Market are:


Gaining Trust: Biosimilars industry will grow at a faster rate if the market can gain the trust of all the physicians, doctors, and patients. These medicines are approved and safe for use but their effectiveness is not guaranteed.


Improved Access to the medicines: Even though these medicines are available at a lower cost, still not everyone can access them. Improve access to these medicines can trigger a better growth of biosimilar medicines.


Regulatory Implications


The Biosimilars Market is all drugs and medicines so regulatory implications come under one of the very important concerns for the market. Government-issued laws and regulations are to be followed and important to be maintained within the market. These regulations are necessary to keep a regular check and maintain a legit way of work within the market. Rules, laws, and regulations are applied from importing drugs, their formulation, their manufacturing, and exportation of the product, everything is kept under surveillance to avoid any form of illegal activity.


Biosimilars Market Segment Overview
The study of a market segment-wise helps to understand the different segments of a particular market. The Biosimilar Market is divided into four major segments which are:


By Molecule: This segment of the Market states the different types of molecular products produced by the Biosimilar Market.



  • Rituximab

  • Infliximab

  • Epoetin Alfa

  • Follitropin Alfa

  • Somatropin

  • Filgrastim

  • Etanercept

  • Insulin Glargine and others.


By Indication: This segment of the biosimilars market includes the chronic diseases for which the products are formulated and manufactured.



  • Autoimmune diseases.

  • Blood disorder

  • Diabetes

  • Oncology

  • Growth Deficiency

  • Off-Site treatment’

  • Allergies

  • Female infertility and others.


By Manufacturing: There is two main division of the Market by Manufacturing segment which are:



  • In-house manufacturing

  • Contract manufacturing


By Region: The biosimilar market is divided into five major regions which are:



  • North America

  • Europe

  • Asia-Pacific

  • The Middle East and Africa

  • Latin America


Regional Analysis:
Global Market Robotics Shares are spread across the five major regions of the world. The highest share of the market is held by Europe as the maximum number of people belonging to the geriatric population then followed by the Asia-Pacific Region. Moreover, Asia-Pacific Region is expected to show significant growth over the forecasted period till 2027. The Global Biosimilar market is divided into major regions namely, North-America, Latin-America, Europe, Asia-Pacific region, Middle East, and Africa.

Competitive Landscape
The Biosimilar Market has a competitive environment as different companies and key players of the market are trying to advertise similar products made of similar drugs. Sometimes, different companies collaborate to form a new product or to work on a single type of vaccine or medicine to treat a lethal disease. 


Given below are the key players of the Biosimilars market-



  • Pfizer (US)

  • Sandoz (Germany)

  • Biocon (India)

  • Biogen (US)

  • Fresenius Kabi AG (Germany)

  • Boehringer Ingelheim (Germany)

  • Merck KgaA (Germany)

  • Mylan (US)

  • Eli Lilly (US)

  • Teva Pharmaceutical (Israel)

  • Dr. Reddy's Laboratories (India)

  • Amgen (US)

  • Celltrion (South Korea)

  • Samsung Biologics (South Korea)

  • Amega Biotech (Argentina)

  • mAbxience (Switzerland)

  • Probiomed (Mexico)

  • Apotex (Canada)

  • Chong Kun Dang (South Korea)

  • JCR Pharmaceuticals (Japan)

  • Gan & Lee Pharmaceuticals (China)

  • Gedeon Richter (Hungary)

  • Biocad (Russia)

  • Coherus Bioscience (US)

  • Stada Arzneimittel AG (Germany)


Recent Developments


From time to time development is registered by the biosimilars market. The developments in this market depend on the invention and discoveries made in the medical field to form new formulations to treat some chronic and critical diseases.


Biosimilar medicines are similar to the original formulation of biological medicine so development depends on that. Apart from this, new technologies and techniques are now used to manufacture cine. Also, key players of the market continuously work to improve the market position and spread the biosimilars market.

Report Overview


The Biosimilars Market research report gives a detailed description of this Market. Starting with the meaning and definition of Biosimilar medicines to the regulatory implications applied on the market, everything is covered in this report. The Biosimilars Market Analysis gives information about the market and allows understanding different aspects of the market through studies of Market drivers, restraints, challenges,  and opportunities open to the market.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2025: 7.5%
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product, Applications and End-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen, Inc. (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), Samsung Biologics (South Korea), Eli Lily & Company (US), Hospira Inc.(US), Actavis, Inc.(US), Cipla Ltd (India), Stada Arzneimittel AG (Germany), and Mylan, Inc.(US).
  Key Market Opportunities   Increasing prevalence of diseases and rising geriatric population has led to grow this market in Europe.
  Key Market Drivers

  • Rising demand for biosimilars due to their cost-effectiveness and growing prevalence of chronic diseases.
  • Rising pressure to reduce healthcare expenditure coupled with patent expiry of various blockbuster drugs


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    For instance, according to the biosimilars update report by Amgen in 2019, As of January 2019, the US Food and Drug Administration (FDA) approved 17 biosimilars, out of which 7 products launched in 4 therapeutic areas.

    A biosimilar is a biologic medical product highly similar to another already approved biological medicine. Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines.

    Biosimilars Market is expected to grow at 7.5% CAGR from 2019 to 2025.

    Biosimilars Market stood at USD 13,460 million in 2018.

    Rising prevalence of diseases and cost-effective production rate of biosimilars can drive the Biosimilars Market.

    Europe is expected to contribute the maximum to the Biosimilars Market.

    Pfizer, Eli Lily & Company, Teva Pharmaceuticals, Stada Arzneimittel AG, Dr. Reddy’s Laboratories, Cipla Ltd, Celltrion, Hospira Inc., Sandoz International, Amgen, Inc., Samsung Biologics, Biocon, Mylan, Inc., Actavis, Inc. are some of the biggest names of the Global Biosimilars Market.

    Table of Contents

    1. REPORT PROLOGUE

    2. MARKET INTRODUCTION

    2.1. Definition

    2.2. Scope of the Study

    2.2.1. Research Objective

    2.2.2. Assumptions

    2.2.3. Limitations

    3. RESEARCH METHODOLOGY

    3.1. Overview

    3.2. Primary Research

    3.3. Secondary Research

    3.4. Market Size Estimation

    4. MARKET DYNAMICS

    4.1. Overview

    4.2. Drivers

    4.3. Restraints

    4.4. Opportunities

    5. MARKET FACTOR ANALYSIS

    5.1. Porter’s Five Forces Analysis

    5.1.1. Bargaining Power of Suppliers

    5.1.2. Bargaining Power of Buyers

    5.1.3. Threat of New Entrants

    5.1.4. Threat of Substitutes

    5.1.5. Intensity of Rivalry

    5.2. Value Chain Analysis


    6. GLOBAL BIOSIMILARS MARKET, BY PRODUCT

    6.1. Overview

    6.2. Recombinant Non-Glycosylated Proteins

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.1. Human Growth Hormone (RHGH)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.2. Granulocyte Colony-Stimulating Factor (Filgrastim)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.3. Insulin

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.4. Interferons

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3. Recombinant Glycosylated Proteins

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3.1. Erythropoietin (EPO)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3.2. Monoclonal Antibodies (MABS)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3.3. Follitropin

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4. Recombinant Peptides

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4.1. Glucagon

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4.2. Calcitonin

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7. GLOBAL BIOSIMILARS MARKET, BY APPLICATIONS

    7.1. Overview

    7.2. Oncology

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3. Chronic Diseases

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4. Autoimmune Diseases

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.5. Blood Disorders

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.6. Growth Hormone Deficiency

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.7. Infectious Diseases

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.8. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8. GLOBAL BIOSIMILARS MARKET, BY END USER

    8.1. Overview

    8.2. Hospitals and Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3. Research Institutes

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9. GLOBAL BIOSIMILARS MARKET, BY REGION

    9.1. Overview

    9.2. Americas

    9.2.1. North America

    9.2.1.1. US

    9.2.1.2. Canada

    9.2.2. Latin America

    9.3. Europe

    9.3.1. Western Europe

    9.3.1.1. Germany

    9.3.1.2. France

    9.3.1.3. Italy

    9.3.1.4. Spain

    9.3.1.5. UK

    9.3.1.6. Rest of Western Europe

    9.3.2. Eastern Europe

    9.4. Asia-Pacific

    9.4.1. Japan

    9.4.2. China

    9.4.3. India

    9.4.4. Australia

    9.4.5. South Korea

    9.4.6. Rest of Asia-Pacific

    9.5. Middle East & Africa

    9.5.1. Middle East

    9.5.2. Africa

    10. COMPANY LANDSCAPE

    10.1. Overview

    10.2. Competitive Analysis

    10.3. Market Share Analysis

    10.4. Major Growth Strategy in the Global Biosimilars Market

    10.5. Competitive Benchmarking

    10.6. Leading Players in Terms of Number of Developments in the Global Biosimilars Market

    10.7. Key developments and Growth Strategies

    10.7.1. Product Launch/Service Deployment

    10.7.2. Mergers and Acquisitions

    10.7.3. Joint Ventures

    10.8. Major Players Financial Matrix & Market Ratio

    10.8.1. Sales & Operating Income 2020

    10.8.2. Major Players R&D Expenditure 2020

    10.9. Major Players Capital Market Ratio

    11. COMPANY PROFILES

    11.1. Pfizer

    11.1.1. Company Overview

    11.1.2. Product Overview

    11.1.3. Financial Overview

    11.1.4. Key Developments

    11.1.5. SWOT Analysis

    11.1.6. Key Strategies

    11.2. Sandoz International

    11.2.1. Company Overview

    11.2.2. Product Overview

    11.2.3. Financial Overview

    11.2.4. Key Developments

    11.2.5. SWOT Analysis

    11.2.6. Key Strategies

    11.3. Teva Pharmaceuticals

    11.3.1. Company Overview

    11.3.2. Product Overview

    11.3.3. Financial Overview

    11.3.4. Key Developments

    11.3.5. SWOT Analysis

    11.3.6. Key Strategies

    11.4. Amgen, Inc.

    11.4.1. Company Overview

    11.4.2. Product Overview

    11.4.3. Financial Overview

    11.4.4. Key Developments

    11.4.5. SWOT Analysis

    11.4.6. Key Strategies

    11.5. Biocon

    11.5.1. Company Overview

    11.5.2. Product Overview

    11.5.3. Financial Overview

    11.5.4. Key Developments

    11.5.5. SWOT Analysis

    11.5.6. Key Strategies

    11.6. Dr. Reddy’s Laboratories

    11.6.1. Company Overview

    11.6.2. Product Overview

    11.6.3. Financial Overview

    11.6.4. Key Developments

    11.6.5. SWOT Analysis

    11.6.6. Key Strategies

    11.7. Celltrion

    11.7.1. Company Overview

    11.7.2. Product Overview

    11.7.3. Financial Overview

    11.7.4. Key Developments

    11.7.5. SWOT Analysis

    11.7.6. Key Strategies

    11.8. Samsung Biologics

    11.8.1. Company Overview

    11.8.2. Product Overview

    11.8.3. Financial Overview

    11.8.4. Key Developments

    11.8.5. SWOT Analysis

    11.8.6. Key Strategies

    11.9. Eli Lily & Company

    11.9.1. Company Overview

    11.9.2. Product Overview

    11.9.3. Financial Overview

    11.9.4. Key Developments

    11.9.5. SWOT Analysis

    11.9.6. Key Strategies

    11.10. Hospira Inc.

    11.10.1. Company Overview

    11.10.2. Product Overview

    11.10.3. Financial Overview

    11.10.4. Key Developments

    11.10.5. SWOT Analysis

    11.10.6. Key Strategies

    11.11. Actavis, Inc.

    11.12. Cipla Ltd

    11.13. Stada Arzneimittel Ag

    11.14. Mylan, Inc.

    11.15. Others

    12. APPENDIX

    12.1. References

    12.2. Related Reports


    LIST OF TABLES

    TABLE 1 GLOBAL BIOSIMILARS MARKET SYNOPSIS, 2020-2027

    TABLE 2 GLOBAL BIOSIMILARS MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

    TABLE 3 GLOBAL BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

    TABLE 4 GLOBAL BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

    TABLE 5 GLOBAL BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

    TABLE 6 GLOBAL BIOSIMILARS MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 7 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

    TABLE 8 NORTH AMERICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

    TABLE 9 NORTH AMERICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

    TABLE 10 US: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

    TABLE 11 US: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

    TABLE 12 US: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

    TABLE 13 CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

    TABLE 14 CANADA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

    TABLE 15 CANADA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

    TABLE 16 LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

    TABLE 17 LATIN AMERICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

    TABLE 18 LATIN AMERICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

    TABLE 19 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

    TABLE 20 EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

    TABLE 21 EUROPE: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

    TABLE 22 WESTERN EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

    TABLE 23 WESTERN EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

    TABLE 24 WESTERN EUROPE: BIOSIMILARS MARKET, BY END USERS E, 2020-2027 (USD MILLION)

    TABLE 25 EASTERN EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

    TABLE 26 EASTERN EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

    TABLE 27 EASTERN EUROPE: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

    TABLE 28 ASIA-PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

    TABLE 29 ASIA-PACIFIC: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

    TABLE 30 ASIA-PACIFIC: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

    TABLE 31 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

    TABLE 32 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

    TABLE 33 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)


    LIST OF FIGURES

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET STRUCTURE OF THE GLOBAL BIOSIMILARS MARKET

    FIGURE 3 MARKET DYNAMICS OF THE GLOBAL BIOSIMILARS MARKET

    FIGURE 4 GLOBAL BIOSIMILARS MARKET SHARE, BY PRODUCT, 2020 (%)

    FIGURE 5 GLOBAL BIOSIMILARS MARKET SHARE, BY APPLICATIONS, 2020 (%)

    FIGURE 6 GLOBAL BIOSIMILARS MARKET SHARE, BY END USERS, 2020 (%)

    FIGURE 7 GLOBAL BIOSIMILARS MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 8 AMERICAS: BIOSIMILARS MARKET SHAR,E BY REGION, 2020 (%)

    FIGURE 9 NORTH AMERICA: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 10 EUROPE: BIOSIMILARS MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 11 WESTERN EUROPE: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 12 ASIA-PACIFIC: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 13 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 14 GLOBAL BIOSIMILARS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 15 PFIZER: KEY FINANCIALS

    FIGURE 16 PFIZER: SEGMENTAL REVENUE

    FIGURE 17 PFIZER: REGIONAL REVENUE

    FIGURE 18 SANDOZ INTERNATIONAL: KEY FINANCIALS

    FIGURE 19 SANDOZ INTERNATIONAL: SEGMENTAL REVENUE

    FIGURE 20 SANDOZ INTERNATIONAL: REGIONAL REVENUE

    FIGURE 21 AMGEN, INC.: KEY FINANCIALS

    FIGURE 22 AMGEN, INC.: SEGMENTAL REVENUE

    FIGURE 23 AMGEN, INC.: REGIONAL REVENUE

    FIGURE 24 TEVA PHARMACEUTICALS: KEY FINANCIALS

    FIGURE 25 TEVA PHARMACEUTICALS: SEGMENTAL REVENUE

    FIGURE 26 TEVA PHARMACEUTICALS: REGIONAL REVENUE

    FIGURE 27 BIOCON: KEY FINANCIALS

    FIGURE 28 BIOCON: SEGMENTAL REVENUE

    FIGURE 29 BIOCON: REGIONAL REVENUE

    FIGURE 30 DR. REDDY’S LABORATORIES: KEY FINANCIALS

    FIGURE 31 DR. REDDY’S LABORATORIES: SEGMENTAL REVENUE

    FIGURE 32 DR. REDDY’S LABORATORIES: REGIONAL REVENUE

    FIGURE 33 CELLTRION: KEY FINANCIALS

    FIGURE 34 CELLTRION: SEGMENTAL REVENUE

    FIGURE 35 CELLTRION: REGIONAL REVENUE

    FIGURE 36 SAMSUNG BIOLOGICS: KEY FINANCIALS

    FIGURE 37 SAMSUNG BIOLOGICS: SEGMENTAL REVENUE

    FIGURE 38 SAMSUNG BIOLOGICS: REGIONAL REVENUE

    FIGURE 39 ELI LILY & COMPANY: KEY FINANCIALS

    FIGURE 40 ELI LILY & COMPANY: SEGMENTAL REVENUE

    FIGURE 41 ELI LILY & COMPANY: REGIONAL REVENUE

    FIGURE 42 HOSPIRA INC.: KEY FINANCIALS

    FIGURE 43 HOSPIRA INC.: SEGMENTAL REVENUE

    FIGURE 44 HOSPIRA INC.: REGIONAL REVENUE

    FIGURE 45 ACTAVIS, INC.: KEY FINANCIALS

    FIGURE 46 ACTAVIS, INC.: SEGMENTAL REVENUE

    FIGURE 47 ACTAVIS, INC.: REGIONAL REVENUE

    FIGURE 48 CIPLA LTD.: KEY FINANCIALS

    FIGURE 49 CIPLA LTD.: SEGMENTAL REVENUE

    FIGURE 50 CIPLA LTD.: REGIONAL REVENUE

    FIGURE 51 STADA ARZNEIMITTEL AG: KEY FINANCIALS

    FIGURE 52 STADA ARZNEIMITTEL AG: SEGMENTAL REVENUE

    FIGURE 53 STADA ARZNEIMITTEL AG: REGIONAL REVENUE

    FIGURE 54 MYLAN, INC.: KEY FINANCIALS

    FIGURE 55 MYLAN, INC.: SEGMENTAL REVENUE

    FIGURE 56 MYLAN, INC.: REGIONAL REVENUE